/5
0 avis
Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)
Archive ouverte
Edité par CCSD -
IF 11.855 . International audience
Consulter en ligne
Chargement des enrichissements...